ACCOUNT

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

CLASSIFIEDS

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Seres Therapeutics, Inc. - Common Stock (NQ:MCRB)

6.110 -0.630 (-9.35%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	154,450
Open	6.730
Bid (Size)	6.030 (500)
Ask (Size)	6.700 (100)
Prev. Close	6.740
Today's Range	6.025 - 6.848
52wk Range	5.310 - 29.98
Shares Outstanding	127,901,391
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study ↗

Today 14:02 EDT

Seres Therapeutics (NASDAQ:MCRB) reported results from an investigator-sponsored study of SER-155 in immune checkpoint inhibitor-related enterocolitis, or irEC, saying the data support further...

Via MarketBeat

MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% ↗

February 12, 2026

The company said that it will continue to seek funding for the SER-155 Phase 2 study.

Via Stocktwits

Performance

YTD	-59.7%	-59.7%
1 Month	-3.5%	-3.5%
3 Month	-29.9%	-29.9%
6 Month	-60.5%	-60.5%
1 Year	-50.6%	-50.6%

More News

The Great Biotech Re-Shoring: Seres Therapeutics and the New Commodity-Driven Era

December 19, 2025

Via MarketMinute

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Which stocks are gapping on Friday? ↗

November 21, 2025

Via Chartmill

Keep an eye on the top gainers and losers in Thursday's session. ↗

November 20, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 20, 2025

Via Benzinga

Seres (MCRB) Q3 2025 Earnings Call Transcript ↗

November 05, 2025

Via The Motley Fool

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 03, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 08, 2025

Via Benzinga

Top movers in Monday's pre-market session ↗

September 08, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 08, 2025

Via Benzinga

Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket ↗

September 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 08, 2025

Via Benzinga

Seres (MCRB) Q2 Loss Narrows 34% ↗

August 06, 2025

Via The Motley Fool

Seres Therapeutics Inc (NASDAQ:MCRB) Reports Q2 2025 Earnings: Narrower EPS Loss but Shares Dip in Pre-Market ↗

August 06, 2025

Via Chartmill

Uncovering Potential: Seres Therapeutics's Earnings Preview ↗

August 05, 2025

Via Benzinga

This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday ↗

May 08, 2025

Via Benzinga

Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday ↗

May 08, 2025

Via Benzinga

Quest Diagnostics Posts Better-Than-Expected Earnings, Joins Pentair, 3M, Danaher And Other Big Stocks Moving Higher On Tuesday ↗

April 22, 2025

Via Benzinga

Stay updated with the stocks that are on the move in today's pre-market session. ↗

April 15, 2025

Via Chartmill

Stay updated with the stocks that are on the move in today's after-hours session. ↗

April 14, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's After-Market Session ↗

April 14, 2025

Via Benzinga

Frequently Asked Questions

Is Seres Therapeutics, Inc. - Common Stock publicly traded?

Yes, Seres Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Seres Therapeutics, Inc. - Common Stock trade on?

Seres Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Seres Therapeutics, Inc. - Common Stock?

The ticker symbol for Seres Therapeutics, Inc. - Common Stock is MCRB on the Nasdaq Stock Market

What is the current price of Seres Therapeutics, Inc. - Common Stock?

The current price of Seres Therapeutics, Inc. - Common Stock is 6.110

When was Seres Therapeutics, Inc. - Common Stock last traded?

The last trade of Seres Therapeutics, Inc. - Common Stock was at 07/10/26 04:00 PM ET

What is the market capitalization of Seres Therapeutics, Inc. - Common Stock?

The market capitalization of Seres Therapeutics, Inc. - Common Stock is 781.48M

How many shares of Seres Therapeutics, Inc. - Common Stock are outstanding?

Seres Therapeutics, Inc. - Common Stock has 781M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.